GEODE CAPITAL MANAGEMENT, LLC - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 111 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q3 2013. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$3,825,000
-2.5%
1,125,202
+7.8%
0.00%0.0%
Q2 2018$3,924,000
+3.5%
1,043,876
+12.6%
0.00%0.0%
Q1 2018$3,790,000
-10.6%
926,708
+1.6%
0.00%0.0%
Q4 2017$4,241,000
-33.1%
912,179
+2.1%
0.00%
-50.0%
Q3 2017$6,341,000
+2.9%
893,176
+4.8%
0.00%0.0%
Q2 2017$6,161,000
+23.7%
852,162
+5.4%
0.00%0.0%
Q1 2017$4,982,000
+13.3%
808,787
+7.8%
0.00%0.0%
Q4 2016$4,398,000
+14.6%
750,517
+3.8%
0.00%0.0%
Q3 2016$3,839,000
-19.4%
723,016
+0.5%
0.00%
-33.3%
Q2 2016$4,761,000
+45.7%
719,245
+2.8%
0.00%
+50.0%
Q1 2016$3,268,000
-2.5%
699,895
+5.4%
0.00%0.0%
Q4 2015$3,352,000
+44.9%
663,857
+1.0%
0.00%
+100.0%
Q3 2015$2,313,000
-63.3%
657,146
+3.9%
0.00%
-75.0%
Q2 2015$6,310,000
-20.9%
632,268
+0.8%
0.00%
-20.0%
Q1 2015$7,982,000
+6.0%
627,032
+17.8%
0.01%
+25.0%
Q4 2014$7,531,000
+4.7%
532,270
+1.8%
0.00%
-20.0%
Q3 2014$7,190,000
-9.8%
522,982
+1.0%
0.01%0.0%
Q2 2014$7,967,000
-5.2%
518,057
+5.1%
0.01%
-16.7%
Q1 2014$8,401,000
+65.4%
493,041
+25.7%
0.01%
+50.0%
Q4 2013$5,080,000
+43.7%
392,306
+12.1%
0.00%
+33.3%
Q3 2013$3,535,000
+40.1%
349,956
+3.6%
0.00%
+50.0%
Q2 2013$2,524,000337,8480.00%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q3 2013
NameSharesValueWeighting ↓
VHCP Management, LLC 700,273$10,770,0005.76%
HARVEY CAPITAL MANAGEMENT INC 932,400$14,340,0005.13%
Camber Capital Management LP 3,000,000$46,140,0003.02%
Baupost Group 10,539,986$162,105,0002.64%
SECTORAL ASSET MANAGEMENT INC 3,741,656$57,547,0002.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,884,409$59,742,0002.40%
Knoll Capital Management, LLC 200,000$3,076,0001.37%
DAFNA Capital Management LLC 92,400$1,421,0001.35%
NORTHPOINTE CAPITAL LLC 892,011$13,719,0001.32%
Rhenman & Partners Asset Management AB 240,000$3,691,0001.10%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders